Resistance to anti-PD-1 therapy is driven by CD30+ regulatory T cell activity



Summary

Resistance to anti-PD-1 immunotherapy, a common cancer treatment, is often linked to the suppressive activity of CD30-expressing regulatory T cells (Tregs). These CD30+ Tregs infiltrate the tumor microenvironment and dampen the immune response, effectively shielding cancer cells from the intended attack by activated T cells. The presence and activity of these CD30+ Tregs hinder the efficacy of anti-PD-1 therapy, suggesting that targeting or inhibiting these cells could improve patient outcomes and restore sensitivity to immunotherapy. Further research focuses on developing strategies to specifically eliminate or neutralize CD30+ Tregs to overcome this resistance mechanism.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!